Top 5 Medical Stocks To Buy Right Now

DOL Fiduciary Rule Foes Say Delay Falls Short of Trump Order

Best Full-Service Investment Firms Ranked by Investors: J.D. Power 2017

5 Long-Term Care Hybrid Perspectives

The National Association of Insurance Commissioners is gathering in Denver now without knowing how the federal government will handle individual major medical coverage in 2018.

The Kansas City, Missouri-based group for state insurance regulators kicked off its spring meeting Thursday, with a session on life insurance actuarial matters. The group will complete the meeting Tuesday, with joint session of its executive committee and its “plenary” — a body that includes the top insurance regulators from all jurisdictions that belong to the NAIC.

Product Filing Window

House Rules is working on a deal that would add new provisions for high-risk patients.

Top 5 Medical Stocks To Buy Right Now: Affimed N.V.(AFMD)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma
  • [By Lisa Levin]

    Shares of Affimed NV (NASDAQ: AFMD) were down around 21 percent to $1.70. Affimed priced its public offering of 10,000,000 of its common shares at $1.80 per common share.

Top 5 Medical Stocks To Buy Right Now: Roche Holding AG (RHHBY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Chugai Pharma (OTCPK:CHGCY) (TYO: 4519) reported that the CFDA accepted its New Drug Application for eldecalcitol, an oral active vitamin D3 derivative for osteoporosis. A Japanese pharma, Chugai is majority-owned (62%) by Roche (OTCQX:RHHBY) [ROG:SIX]. In a China Phase III trial, patients treated with eldecalcitol showed greater bone mineral density (BMD) compared to alfacalcidol-treated patients after 12 months. Chugai has marketed eldecalcitol in Japan since 2011.

  • [By WWW.KIPLINGER.COM]

    EFAV is another low-volatility product, this one centered around the MSCI EAFE Index, an ex-U.S./Canada index that includes companies in developed markets across Europe, Australasia and the Far East. EFAV uses Barras multi-factor risk model to weed out the riskiest MSCI EAFE Index stocks, resulting in a current 230-stock low-vol portfolio stuffed with stable blue chips. Stocks like multinational foods giant Nestle SA (NSRGY) and healthcare giant Roche Holding Ltd. (RHHBY) line EFAVs top holdings, and help throw off a decent yield of about 2.5%.

  • [By Keith Speights]

    Eisai (NASDAQOTH:ESALY), Novo Nordisk (NYSE:NVO), and Roche Holding Ltd. (NASDAQOTH:RHHBY) fit that description well. Each of these companies markets obesity drugs, but each also sells a broad array of other products with multiple pipeline candidates potentially on the way. Here’s why Eisai, Novo Nordisk, and Roche rank as the three best obesity-drug stocks to buy in 2017.

Top 5 Medical Stocks To Buy Right Now: Reynolds American Inc(RAI)

Advisors’ Opinion:

  • [By Leo Sun]

    With interest rates set to rise this year, many dividend investors are likely worried that their stocks will slip as bond yields become more attractive. While some dividend stocks will inevitably decline, investors can still find some low-risk income plays that have high yields and cheap valuations. Let’s take a look at three such stocks — AT&T (NYSE:T), Cisco Systems (NASDAQ:CSCO), and Reynolds American (NYSE:RAI).

  • [By Ben Levisohn]

    Just before 1pm today, shares of Reynolds American (RAI) took a sudden nosedive on reports that its merger with British American Tobacco (BTI) had “hit a snag” according to StreetInsider.com. Cowen’s Vivien Azer and team still think a deal gets done:

    Getty Images

    Street Insider is reporting that BATS’ acquisition of RAI has “hit a snag,” and that “a potential transaction may be less likely near-term.” We view this source as less credible (vs. a WSJ or CNBC), in particular given the scant level of detail. While the delay in a consummated deal has extended longer than we thought, we still view the deal as likely (85% probability).

    Shares of Reynolds American have dropped 1.3% to $55.47 at 2:26 p.m. today, while British American Tobacco has declined 0.2% to $112.71. Shares of Philip Morris International (PM), which could be interested in an acquisition of Altria Group (MO), have fallen 1% to$90.28 after getting cut toNeutral from Buy at BofA Merrill Lynch, while Altria has risen 0.5% to$67.94 after getting upgraded to Buy from Neutral at Merrill.

  • [By Rich Duprey, Demitrios Kalogeropoulos, and Brian Feroldi]

    It remains true that the tobacco industry will continue coming under pressure from anti-smoking activists, politicians, and regulators who seek to stub out cigarettes further by raising taxes on smokes, but companies such as Altria and Reynolds American (NYSE:RAI) are largely able to offset their impact on profits by raising prices. The ability to command such pricing power without an overly large loss of customers obviously speaks to the addictive qualities of smoking but is also an otherwise enviable position to be in.

Top 5 Medical Stocks To Buy Right Now: Kate Spade & Company(KATE)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Coach (COH) rose to the top of the S&P 500 today after reports that Kate Spade (KATE) had put itself up for sale caused shares of fashion-accessory retailers to rise.

  • [By Steve Symington]

    Shares of Kate Spade & Company (NYSE:KATE) fell 25.1% in the month of April,according to data provided byS&P Global Market Intelligence, after reports that the luxury lifestyle-products specialist wanted more time to consider a buyout offer, then announced disappointing first-quarter 2017 results.

  • [By Ben Levisohn]

    Kate Spade (KATE) caught a bounce on Wednesday when the Wall Street Journalreported that it was actively seeking a buyer. Since then, we’ve learned that the fashion accessories retailer looks set to auction itself off to the highest bidder, with the process potentially beginning next month, with bidders potentially including Coach (COH) and Michael Kors (KORS). In a note today, SunTrust Robinson Humphrey analystPamela Quintiliano and team contend that Kate Spade could fetch as much as $23 a share:

    Getty Images

    Looking at recent historical deals, we arrive at a $18-$23 potential deal range. We analyzed transactions that have been announced over the past four years and involved companies catering to a higher income customer. These deals include Southern Tide (acquired by Oxford Industries (OXM)), Joe’s Jeans (acquired by Sequential Brands Group (SQBG)), prAna (acquired by Columbia Sportswear (COLM)), The Jones Group (acquired by Sycamore Partners [private] and Juicy Couture (acquired by Authentic Brands Group [private]). The average EV/EBITDA multiple of these transactions are 12.9x (in line with KATE’s 5-year historical average of 12.1x) and implies a potential deal range of $22-$23. When taking the average of recent (F13-16) deals implies an ~10.5x EV/EBITDA multiple. When applying the ~10.5x multiples to KATE’s trailing EBITDA, we arrive at an $18- $19 potential share price.

    Shares of Kate Spade have gained 1.1% to $18.70 at 2:08 p.m. today, while Coach has declined 0.2% to $34.95, Michael Kors is little changed at $42.86, Oxford Industries has fallen 0.7% to $60.38, Columbia Sportswear has climbed 1.4% to $58.60, and Sequential Brands Group has jumped 3.7% to $4.77.

  • [By Ben Levisohn]

    Ever since peaking in late April, Kate Spade’s (KATE) shares have been in a downward spiral so pronounced that even an amateur technical analyst like myself could draw its trend line lower. Today, however, its shares are soaring after the Wall Street Journal reported that Kate Spade was actively seeking a buyer.

    Getty Images

    Mizuho’s Betty Chen and Alex Pham run the math on a possible acquisition price:

    When we examined historical transactions in the specialty retail sector, we noticed a wide range of valuations. Select relevant transactions to consider would be ~2x EV/Sales Coach (COH) paid for Stuart Weitzman, Samsonites acquisition of Tumi at 14x EV/EBITDA, 13x EV/EBITDA for Joseph A. Banks by Mens Wearhouse (TLRD) and Kerings acquisition of Volcom for 18x EV/EBITDA. We believe potential valuation could be as high as ~2x EV/ Sales and ~14x EV/EBITDA given Kate Spade’s unique growth profile to expand to ~$4bn in revenue (from $1.4bn in FY16) and improving profitability from 12% EBIT margin TY to at least HTeens-LDD, in our view (Coach is 18.7% and Michael Kors (KORS) is 21.3%). On these two metrics, Kate Spade would be valued at $21-23…

    We believe the growth profile coupled with the brands unique appeal to Millennials and broad-based success across categories ranging from handbags to apparel and jewelry could be attractive to many buyers, including Coach, which was rumored to be evaluating the company in recent weeks.

    The news has sent shares of Kate Spade soaring: They’re up 24% at $18.03 at 2:11 p.m., a gain that has turned this year’s 18% loss as of last night into a 2% gain during afternoon trading.

    The move has also put a dent in Kate Spade’s downtrend (and now you’ll see my amateur technical analysis abilities at work):

    FactSet

    That’s one way to break a downtrend.

Top 5 Medical Stocks To Buy Right Now: Fitbit, Inc.(FIT)

Advisors’ Opinion:

  • [By Brian Withers]

    Fitbit’s(NYSE:FIT) management team was challenged with disappointing device sales last quarter, and James Park, Fitbit’s CEO, indicated the problem was a mass market adoption issue.

  • [By Paul Ausick]

    Fitbit Inc. (NYSE: FIT) lost about 2.4% Tuesday to post a new 52-week low of $8.20 after closing Monday at $8.40. The 52-week high is $34.68. Volume of around 7.1 million was about 30% below the daily average of around 1 million shares traded. The company had no specific news Tuesday.

  • [By Trey Thoelcke]

    Fitbit Inc. (NYSE: FIT) is set to release its first-quarter results after the closing bell on Wednesday. The consensus forecast calls for a net loss of $0.20 per share and $247.56 million in revenue. Shares traded on Fridays close at $5.30. The consensus price target is $6.13, and the 52-week range is $4.51 to $7.32.

  • [By Matthew Cochrane]

    In January 2016, Mastercard reached an agreement with the wearable payment platform Coin, in a collaboration to introduce more payment features in wearables. Since the collaboration, Coin was acquired by Fitbit Inc(NYSE:FIT), meaning Mastercard might have an early edge among payments companies to break into the wearable market in a big way.

  • [By Leo Sun]

    Under Armour (NYSE:UA) (NYSE:UAA), Fitbit (NYSE:FIT), and GoPro (NASDAQ:GPRO) were all terrible stocks to own over the past year. Under Armour and Fitbit were both cut in half, and GoPro plummeted nearly 40%.

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

Leave a Reply

Your email address will not be published. Required fields are marked *